NVCA is Ready to Rock PDF Print E-mail

Emily Mendell

Written by Emily Mendell   

As Jason Mendelson shared today in his blog , a key ingredient of VentureScape 2013 -  NVCA’s  Annual Meeting -  is fun.  And boy did we have fun shooting this video to promote NVCA Live! presented by Silicon Valley Bank.

Watch Now!


That’s Jason as our dreamer, along with by Ray Rothrock of Venrock (and NVCA chairman) and Marc Cadieux of SVB.  These three talented musicians will be performing at NVCA Live! on March 14th at the Great American Music Hall with their bands Legitimate Front, Up and to The Right, and The Exploding Warrants.  The evening will culminate in a private concert by Train lead singer Pat Monahan and his trio.

More information on this party and concert, which also includes outstanding food and open bar courtesy of Merrill Lynch and Cooley, can be found here.

Want tickets?  Sure thing.

If you are an NVCA member, you can purchase them for yourself and all your friends here.

If you are a member of the press, email me (emendell@nvca.org)  as there are a limited number of passes I can offer.

If you are not either of those folks, connect with your favorite NVCA member and ask them to buy you a ticket.  Guests are welcome!!

Advance tickets are required for entry.  They must be purchased separate from VentureScape registration.  No sales will be made at the door.  We are planning to sell out, so get tickets soon.

We are ready to rock.  Hope many of you will join us.





Final FATCA Regulations and Deadlines Issued PDF Print E-mail

John Taylor

Written by John Taylor   

On January 17, 2013, the U.S. Department of the Treasury and U.S. Internal Revenue Service (IRS) issued final Treasury Regulations under the tax provisions commonly referred to as the Foreign Account Tax Compliance Act (FATCA). The full alert from Proskauer can be found here. The mobile version is also available.

There is quite a rubric of rules which could apply to venture firms and funds with any kind of foreign presence or affiliated entity. Member general counsel and CFOs need to be familiar with these new rules which are specified in a 543-page IRS document.

Last Updated on Thursday, 21 February 2013 14:32




NVCA Seeks to Expand Corporate VC Data Collection PDF Print E-mail

Janice Mawson

Written by Janice Mawson   
Last week, the NVCA announced a new data collection initiative with Thomson Reuters, to promote and report the depth and powerful impact of corporate venture capital (CVC) investing.  A recent revamp in Thomson Reuters’s definition of CVC will allow them to capture all CVC investments regardless of syndicate makeup, round sequencing, investing company’s corporate structure, or virtually any deal whether it is strategic or financial in nature.  Historically we have only captured CVC investment if it is part of a syndicate of traditional VC investors.  
However, our success depends on the participation of corporate VC investors.
An invitation for corporations to contribute to Thomson Reuters' surveys can be found here.  We are asking corporations to begin the process by developing or updating their company profile and contact information at Thomson Reuters by connecting with Donald Fleurantin at donald.fleuratin@thomsonreuters.com.
As many know, Thomson Reuters data powers the quarterly MoneyTree Reports and maximum participation will help ensure that CVC deals and data are included to the fullest extent possible.
Thanks to all those who participate and please feel free to contact me at jmawson@nvca.org with any questions.

Last Updated on Tuesday, 19 February 2013 10:11




NVCA Launches BIG:VC Study PDF Print E-mail

Emily Mendell

Written by Emily Mendell   

On Friday, the NVCA, along with our partners at Dow Jones Venture Source, DeSantis Breindel and Rooney & Associates launched a first-time survey called the Brand Influence Guide for Venture Capital or BIG: VC.

The survey was borne from a proposal to NVCA from the NY based branding and PR firms DeSantis Breindel and Rooney & Associates to explore how brand perception is viewed in the venture capital industry.  Does a VC firm’s brand matter?  To founders?  To LPs?  To one another?

This topic is one with which the venture industry has been grappling in the last few years as more and more firms are focusing on building their unique brands to attract investors and strengthen deal flow.  But what really resonates with the audiences so important to our industry?  What brand attributes make a difference? And how does a firm best convey the strengths it chooses to put forth?

It was a series of questions we at NVCA wanted to answer.  We worked closely with some of the best marketing and communications professionals in the venture industry to design the survey and we expect the results to be extremely enlightening.

The survey – which comprises separate questions for VCs, CEOs and LPs - will run through the month of February.  If you are a venture professional, company founder or limited partner in a venture fund and want to take 5 minutes to give us your thoughts on brand perception within the VC industry, please email me at emendell@nvca.org and I will get you the link.  All survey respondents have the option to receive final results.

We hope to hear from you!





Raising Money In Emerging Markets - Fairytale? PDF Print E-mail

Jeanne Metzger

Written by Jeanne Metzger   

There has been a lot of discussion in recent months about the viability of raising venture capital funds from international capital sources. The challenge for many in the U.S. venture capital market is that with limited experience and knowledge of these emerging markets it's challenging to develop an effective strategy. To help in this regard, NVCA recently asked O'Meleveny & Myers LLP to create a white paper about the fundraising landscape in the emerging markets they have seen venture capitalists successfully raise money.

Today, NVCA released this paper to its membership and we encourage anyone interested in learning more about the fundraising landscape overseas to take a look. The piece discusses China, Japan, Singapore, South Korea, Peru, Chile, and Brazil. The authors highlight why each market is worth considering, who the key LPs are, and the regulatory hurdles to consider.

Click here to read the white paper.

We hope you find this article useful and would love to hear feedback about its content and related value to your business. Feel free to email me at jmetzger@nvca.org.

Over the coming months, keep a look out as we add more content to the NVCA website relating to fundraising, VC firm management and LP relations.





Jim Healy Presents at FDA Hearing on Special Medical Use Pathway PDF Print E-mail

Kelly Sloane

Written by Kelly Slone   

On February 4, FDA held a public hearing on a new proposal that would create an alternative approval pathway for certain drugs intended to address unmet medical need, also referred to as a Special Medical Use (SMU) designation.  Jim Healy, Managing General Partner, Sofinnova Ventures, presented NVCA’s perspective on the proposed new pathway before the FDA panel.

The SMU pathway was one of the recommendations that came out of the President’s Council of Advisors on Science and Technology (PCAST) report released last September entitled, “Report to the President on Propelling Innovation in Drug Discovery, Development, and Evaluation,” as a way to improve drug evaluation.

Under the proposed SMU pathway, the drug’s safety and effectiveness would be studied in a smaller subpopulation of patients with more serious manifestations of a condition and would likely involve smaller and more rapid clinical trials.  NVCA believes this new pathway could improve research and discovery in novel therapeutic areas, reduce the risk to patients and companies in the development of new treatments and encourage renewed funding of disease areas that are currently viewed as too risky or costly.

NVCA appreciates FDA’s continued efforts to explore thoughtful ways to increase patient access to innovative treatments.  We look forward to participating in an open dialogue with all stakeholders in working out the details of the SMU pathway.  There is tremendous promise here to promote innovation and improve discovery, development and regulatory review of new innovative treatments for important unmet medical needs.

Last Updated on Thursday, 07 February 2013 10:43
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 10 of 37